Bifidobacterium pseudocatenulatumcapsular exopolysaccharide enhances systemic anti-tumour immunity in pre-clinical breast cancer

Abstract Gut microbes have merged as powerful regulators of cancer responses, with Bifidobacterium species and strains playing a key role in promoting anti-tumour immunity. While they represent promising candidates for cancer therapeutics, the specific underlying microbial mechanisms driving their efficacy remains poorly understood. In this study, we demonstrate the broad potential of Bifidobacterium species to inhibit breast cancer progression across multiple pre-clinical mouse models. We identify a novel strain, Bifidobacterium pseudocatenulatum 210, which induces systemic anti-tumour immunity and enhances responses to standard-of-care therapies via its cell surface capsular exopolysaccharide (EPS). B. pseudocatenulatum 210 EPS promotes dendritic cell activation and increases systemic cDC1 infiltration, leading to robust CD8+ T cell-mediated anti-tumour activity. Our findings position Bifidobacterium EPS as a novel class of therapeutic compounds with significant potential for cancer treatment. Competing Interest Statement CAP, MK, LJH, and SDR are inventors on patent GB 2413717.6 submitted by Bailey Walsh & CO LLP that covers the use of the exopolysaccharide compositions. All other authors declare no competing interests.